(IN BRIEF) GSK announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults in the EU with uncontrolled COPD characterised by raised blood eosinophils who are already receiving inhaled triple therapy, making it the … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged American Thoracic Society, blood eosinophils, COPD, CRSwNP, EGPA, emergency department visits, eosinophilic phenotype, European Commission, European Federation of Allergy and Airways Diseases Patients’ Associations, Exacerbations, GSK, GSK Expands Nucala’s European Indications with Landmark Approval for Uncontrolled COPD, GSK Strengthens Its Respiratory Portfolio as Nucala Receives EU Approval for Add-On COPD Treatment, HES, hospitalisations, IL-5, inhaled triple therapy, Kaivan Khavandi, MATINEE trial, mepolizumab, New England Journal of Medicine, Nucala, Phase III, respiratory medicine, Severe Asthma, Susanna Palkonen, type 2 inflammation
(IN BRIEF) GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s Ministry of Health, Labour and Welfare, the therapy delivers sustained disease control … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ANCHOR trials, asthma exacerbations, chronic rhinosinusitis with nasal polyps, CRSwNP, Depemokimab, Exdensur, Exdensur Gains Approval in Japan, Expanding GSK’s Respiratory Biologic Portfolio, GSK, GSK’s Depemokimab Approved in Japan, interleukin 5, Introducing New Option for Severe Asthma Care, Japan Ministry of Health Labour and Welfare, Kaivan Khavandi, Nasal Polyps, respiratory medicine, Severe Asthma, SWIFT trials, type 2 inflammation, ultra long acting biologic
(IN BRIEF) AstraZeneca’s inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk of severe asthma exacerbations in patients with intermittent or mild persistent asthma, according to high-level results from the BATURA Phase IIIb trial. The trial … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Airsupra, AstraZeneca, Professor James Donohue, safety, Severe Asthma, Sharon Barr
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?